Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 260

1.

Adaptation of hepatitis C virus to interferon lambda polymorphism across multiple viral genotypes.

Chaturvedi N, Svarovskaia ES, Mo H, Osinusi AO, Brainard DM, Subramanian GM, McHutchison JG, Zeuzem S, Fellay J.

Elife. 2019 Sep 3;8. pii: e42542. doi: 10.7554/eLife.42542.

2.

Computational-observer analysis of illumination discrimination.

Ding X, Radonjic A, Cottaris NP, Jiang H, Wandell BA, Brainard DH.

J Vis. 2019 Jul 1;19(7):11. doi: 10.1167/19.7.11.

3.

What is cognition?

Bayne T, Brainard D, Byrne RW, Chittka L, Clayton N, Heyes C, Mather J, Ölveczky B, Shadlen M, Suddendorf T, Webb B.

Curr Biol. 2019 Jul 8;29(13):R608-R615. doi: 10.1016/j.cub.2019.05.044.

PMID:
31287972
4.

A Conversation with Jacob Nachmias.

Nachmias J, Movshon JA, Wandell BA, Brainard DH.

Annu Rev Vis Sci. 2019 Sep 15;5:1-13. doi: 10.1146/annurev-vision-011019-111539. Epub 2019 Jul 5.

PMID:
31283448
5.

Visual Function at the Atrophic Border in Choroideremia Assessed with Adaptive Optics Microperimetry.

Tuten WS, Vergilio GK, Young GJ, Bennett J, Maguire AM, Aleman TS, Brainard DH, Morgan JIW.

Ophthalmol Retina. 2019 Oct;3(10):888-899. doi: 10.1016/j.oret.2019.05.002. Epub 2019 May 8.

PMID:
31235310
6.

Sofosbuvir and Ribavirin Therapy for Children Aged 3 to <12 Years With Hepatitis C Virus Genotype 2 or 3 Infection.

Rosenthal P, Schwarz KB, Gonzalez-Peralta RP, Lin CH, Kelly DA, Nightingale S, Balistreri WF, Bansal S, Jonas MM, Massetto B, Brainard DM, Hsueh CH, Shao J, Parhy B, Davison S, Feiterna-Sperling C, Gillis LA, Indolfi G, Sokal EM, Murray KF, Wirth S.

Hepatology. 2019 Jun 20. doi: 10.1002/hep.30821. [Epub ahead of print]

PMID:
31222783
7.

Ledipasvir-Sofosbuvir for 12 Weeks in Children 3 to <6 Years Old With Chronic Hepatitis C.

Schwarz KB, Rosenthal P, Murray KF, Honegger JR, Hardikar W, Hague R, Mittal N, Massetto B, Brainard DM, Hsueh CH, Shao J, Parhy B, Narkewicz MR, Rao GS, Whitworth S, Bansal S, Balistreri WF.

Hepatology. 2019 Jun 20. doi: 10.1002/hep.30830. [Epub ahead of print]

PMID:
31220349
8.

Ledipasvir/Sofosbuvir for 8 Weeks to Treat Acute Hepatitis C Virus Infections in Men With Human Immunodeficiency Virus Infections: Sofosbuvir-Containing Regimens Without Interferon for Treatment of Acute HCV in HIV-1 Infected Individuals.

Naggie S, Fierer DS, Hughes MD, Kim AY, Luetkemeyer A, Vu V, Roa J, Rwema S, Brainard DM, McHutchison JG, Peters MG, Kiser JJ, Marks KM, Chung RT; Acquired Immunodeficiency Syndrome Clinical Trials Group (ACTG) A5327 Study Team .

Clin Infect Dis. 2019 Mar 28. pii: ciy913. doi: 10.1093/cid/ciy913. [Epub ahead of print]

PMID:
31220220
9.

Deferred treatment with a fixed-dose combination of sofosbuvir-velpatasvir for chronic hepatitis C virus genotype 1, 2, 4 and 6 infection.

Asselah T, Shafran SD, Bourgeois S, Lai CL, Mathurin P, Willems B, Nguyen MH, Davis MN, Huang KC, Svarovskaia E, Osinusi A, McNally J, Brainard DM, Shaikh OS, Tran TT.

J Viral Hepat. 2019 Oct;26(10):1229-1232. doi: 10.1111/jvh.13159. Epub 2019 Aug 4.

PMID:
31216086
10.

Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial.

Stellbrink HJ, Arribas JR, Stephens JL, Albrecht H, Sax PE, Maggiolo F, Creticos C, Martorell CT, Wei X, Acosta R, Collins SE, Brainard D, Martin H.

Lancet HIV. 2019 Jun;6(6):e364-e372. doi: 10.1016/S2352-3018(19)30080-3. Epub 2019 May 5.

PMID:
31068272
11.

Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial.

Wohl DA, Yazdanpanah Y, Baumgarten A, Clarke A, Thompson MA, Brinson C, Hagins D, Ramgopal MN, Antinori A, Wei X, Acosta R, Collins SE, Brainard D, Martin H.

Lancet HIV. 2019 Jun;6(6):e355-e363. doi: 10.1016/S2352-3018(19)30077-3. Epub 2019 May 5.

PMID:
31068270
12.

The relative contribution of color and material in object selection.

Radonjić A, Cottaris NP, Brainard DH.

PLoS Comput Biol. 2019 Apr 12;15(4):e1006950. doi: 10.1371/journal.pcbi.1006950. eCollection 2019 Apr.

13.

A computational-observer model of spatial contrast sensitivity: Effects of wave-front-based optics, cone-mosaic structure, and inference engine.

Cottaris NP, Jiang H, Ding X, Wandell BA, Brainard DH.

J Vis. 2019 Apr 1;19(4):8. doi: 10.1167/19.4.8.

PMID:
30943530
14.

Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials.

Gupta SK, Post FA, Arribas JR, Eron JJ Jr, Wohl DA, Clarke AE, Sax PE, Stellbrink HJ, Esser S, Pozniak AL, Podzamczer D, Waters L, Orkin C, Rockstroh JK, Mudrikova T, Negredo E, Elion RA, Guo S, Zhong L, Carter C, Martin H, Brainard D, SenGupta D, Das M.

AIDS. 2019 Jul 15;33(9):1455-1465. doi: 10.1097/QAD.0000000000002223.

15.

Illumination discrimination for chromatically biased illuminations: Implications for color constancy.

Aston S, Radonjic A, Brainard DH, Hurlbert AC.

J Vis. 2019 Mar 1;19(3):15. doi: 10.1167/19.3.15.

16.

Comparison of the efficacy of sofosbuvir plus ribavirin in Chinese patients with genotype 3a or 3b HCV infection.

Huang R, Rao H, Xie Q, Gao Z, Li W, Jiang D, Mo H, Massetto B, Stamm LM, Brainard DM, Wei L.

J Med Virol. 2019 Jul;91(7):1313-1318. doi: 10.1002/jmv.25454. Epub 2019 Apr 3.

PMID:
30861150
17.

Probing Computation in the Primate Visual System at Single-Cone Resolution.

Kling A, Field GD, Brainard DH, Chichilnisky EJ.

Annu Rev Neurosci. 2019 Jul 8;42:169-186. doi: 10.1146/annurev-neuro-070918-050233. Epub 2019 Mar 11.

PMID:
30857477
18.

Sofosbuvir-velpatasvir single-tablet regimen administered for 12 weeks in a phase 3 study with minimal monitoring in India.

Sood A, Duseja A, Kabrawala M, Amrose P, Goswami B, Chowdhury A, Sarin SK, Koshy A, Hyland RH, Lu S, Camus G, Stamm LM, Brainard DM, Subramanian GM, Prasad M, Bhatia S, Shah SR, Kapoor D, Shalimar, Saraswat V.

Hepatol Int. 2019 Mar;13(2):173-179. doi: 10.1007/s12072-019-09927-6. Epub 2019 Feb 21.

19.

Sofosbuvir/Velpatasvir/Voxilaprevir for patients with HCV who previously received a Sofosbuvir/Velpatasvir-containing regimen: Results from a retreatment study.

Ruane P, Strasser SI, Gane EJ, Hyland RH, Shao J, Dvory-Sobol H, Tran T, Stamm LM, Brainard DM, Nyberg L, Shafran S.

J Viral Hepat. 2019 Jun;26(6):770-773. doi: 10.1111/jvh.13067. Epub 2019 Feb 27.

PMID:
30663168
20.

Computational luminance constancy from naturalistic images.

Singh V, Cottaris NP, Heasly BS, Brainard DH, Burge J.

J Vis. 2018 Dec 3;18(13):19. doi: 10.1167/18.13.19.

21.

Sofosbuvir, Velpatasvir, and Voxilaprevir for Treatment of Recurrent Hepatitis C Virus Infection After Liver Transplantation.

Cardona-Gonzalez MG, Goldman JD, Narayan L, Brainard DM, Kowdley KV.

Hepatol Commun. 2018 Nov 14;2(12):1446-1450. doi: 10.1002/hep4.1280. eCollection 2018 Dec.

22.

Sofosbuvir-velpatasvir for treatment of chronic hepatitis C virus infection in Asia: a single-arm, open-label, phase 3 trial.

Wei L, Lim SG, Xie Q, Văn KN, Piratvisuth T, Huang Y, Wu S, Xu M, Tang H, Cheng J, Le Manh H, Gao Y, Mou Z, Sobhonslidsuk A, Dou X, Thongsawat S, Nan Y, Tan CK, Ning Q, Tee HP, Mao Y, Stamm LM, Lu S, Dvory-Sobol H, Mo H, Brainard DM, Yang YF, Dao L, Wang GQ, Tanwandee T, Hu P, Tangkijvanich P, Zhang L, Gao ZL, Lin F, Le TTP, Shang J, Gong G, Li J, Su M, Duan Z, Mohamed R, Hou JL, Jia J.

Lancet Gastroenterol Hepatol. 2019 Feb;4(2):127-134. doi: 10.1016/S2468-1253(18)30343-1. Epub 2018 Dec 14.

PMID:
30555048
23.

Simulation of visual perception and learning with a retinal prosthesis.

Golden JR, Erickson-Davis C, Cottaris NP, Parthasarathy N, Rieke F, Brainard DH, Wandell BA, Chichilnisky EJ.

J Neural Eng. 2019 Apr;16(2):025003. doi: 10.1088/1741-2552/aaf270. Epub 2018 Nov 20.

PMID:
30523985
24.

Sofosbuvir/velpatasvir for the treatment of HCV: excellent results from a phase-3, open-label study in Russia and Sweden.

Isakov V, Chulanov V, Abdurakhmanov D, Burnevich E, Nurmukhametova E, Kozhevnikova G, Gankina N, Zhuravel S, Romanova S, Hyland RH, Lu S, Svarovskaia ES, McNally J, Brainard DM, Ivashkin V, Morozov V, Bakulin I, Lagging M, Zhdanov K, Weiland O.

Infect Dis (Lond). 2019 Feb;51(2):131-139. doi: 10.1080/23744235.2018.1535186. Epub 2018 Nov 30.

PMID:
30499360
25.

Pulses of Melanopsin-Directed Contrast Produce Highly Reproducible Pupil Responses That Are Insensitive to a Change in Background Radiance.

McAdams H, Igdalova A, Spitschan M, Brainard DH, Aguirre GK.

Invest Ophthalmol Vis Sci. 2018 Nov 1;59(13):5615-5626. doi: 10.1167/iovs.18-25219.

26.

Sofosbuvir/velpatasvir for patients with chronic genotype 3 HCV infection with compensated cirrhosis: Response to EASL Recommendations on Treatment of Hepatitis C 2018.

Stamm LM, Brainard DM, McHutchison JG.

J Hepatol. 2019 Mar;70(3):561-562. doi: 10.1016/j.jhep.2018.08.029. Epub 2018 Nov 13. No abstract available.

PMID:
30445102
27.

Efficacy and safety of sofosbuvir-velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis: an open-label phase 3 trial.

Takehara T, Sakamoto N, Nishiguchi S, Ikeda F, Tatsumi T, Ueno Y, Yatsuhashi H, Takikawa Y, Kanda T, Sakamoto M, Tamori A, Mita E, Chayama K, Zhang G, De-Oertel S, Dvory-Sobol H, Matsuda T, Stamm LM, Brainard DM, Tanaka Y, Kurosaki M.

J Gastroenterol. 2019 Jan;54(1):87-95. doi: 10.1007/s00535-018-1503-x. Epub 2018 Sep 10.

28.

Pharmacokinetics, Safety, and Tolerability of the Direct-acting Hepatitis C Antiviral Sofosbuvir in HealthyChineseSubjects.

Li X, Chen H, Niu J, Chen G, Shen G, Massetto B, Brainard DM, Zhu X, Zhang H, Ding Y.

Clin Ther. 2018 Sep;40(9):1556-1566. doi: 10.1016/j.clinthera.2018.07.018. Epub 2018 Sep 2.

PMID:
30185395
29.

HCV phylogenetic signature and prevalence of pretreatment NS5A and NS5B NI-Resistance associated substitutions in HCV-Infected patients in Mainland China.

Wei L, Omata M, Lim YS, Xie Q, Hou JL, Jia J, Hedskog C, Martin R, Doehle B, Yang J, De-Oertel S, Massetto B, Kersey K, Brainard DM, Svarovskaia E, Mo H, Han KH, Mizokami M, Duan Z.

Antiviral Res. 2018 Oct;158:178-184. doi: 10.1016/j.antiviral.2018.08.001. Epub 2018 Aug 16.

PMID:
30120954
30.

Neuronal population mechanisms of lightness perception.

Ruff DA, Brainard DH, Cohen MR.

J Neurophysiol. 2018 Nov 1;120(5):2296-2310. doi: 10.1152/jn.00906.2017. Epub 2018 Aug 15.

PMID:
30110233
31.

Spatial summation in the human fovea: Do normal optical aberrations and fixational eye movements have an effect?

Tuten WS, Cooper RF, Tiruveedhula P, Dubra A, Roorda A, Cottaris NP, Brainard DH, Morgan JIW.

J Vis. 2018 Aug 1;18(8):6. doi: 10.1167/18.8.6.

32.

No impact of resistance-associated substitutions on the efficacy of sofosbuvir, velpatasvir, and voxilaprevir for 12 weeks in HCV DAA-experienced patients.

Sarrazin C, Cooper CL, Manns MP, Reddy KR, Kowdley KV, Roberts SK, Dvory-Sobol H, Svarovskia E, Martin R, Camus G, Doehle BP, Stamm LM, Hyland RH, Brainard DM, Mo H, Gordon SC, Bourliere M, Zeuzem S, Flamm SL.

J Hepatol. 2018 Dec;69(6):1221-1230. doi: 10.1016/j.jhep.2018.07.023. Epub 2018 Aug 9.

PMID:
30098373
33.

Safety and Efficacy of Ledipasvir-Sofosbuvir With or Without Ribavirin for Chronic Hepatitis C in Children Ages 6-11.

Murray KF, Balistreri WF, Bansal S, Whitworth S, Evans HM, Gonzalez-Peralta RP, Wen J, Massetto B, Kersey K, Shao J, Garrison KL, Parhy B, Brainard DM, Arnon R, Gillis LA, Jonas MM, Lin CH, Narkewicz MR, Schwarz K, Rosenthal P.

Hepatology. 2018 Dec;68(6):2158-2166. doi: 10.1002/hep.30123. Epub 2018 Nov 17.

PMID:
30070726
34.

Sofosbuvir-velpatasvir plus ribavirin in Japanese patients with genotype 1 or 2 hepatitis C who failed direct-acting antivirals.

Izumi N, Takehara T, Chayama K, Yatsuhashi H, Takaguchi K, Ide T, Kurosaki M, Ueno Y, Toyoda H, Kakizaki S, Tanaka Y, Kawakami Y, Enomoto H, Ikeda F, Jiang D, De-Oertel S, McNabb BL, Camus G, Stamm LM, Brainard DM, McHutchison JG, Mochida S, Mizokami M.

Hepatol Int. 2018 Jul;12(4):356-367. doi: 10.1007/s12072-018-9878-6. Epub 2018 Jul 20.

35.

Identification of a Novel Hepatitis C Virus Genotype From Punjab, India: Expanding Classification of Hepatitis C Virus Into 8 Genotypes.

Borgia SM, Hedskog C, Parhy B, Hyland RH, Stamm LM, Brainard DM, Subramanian MG, McHutchison JG, Mo H, Svarovskaia E, Shafran SD.

J Infect Dis. 2018 Oct 20;218(11):1722-1729. doi: 10.1093/infdis/jiy401.

PMID:
29982508
36.

Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With Hepatitis C Virus Genotype 3 Infection and Cirrhosis.

Esteban R, Pineda JA, Calleja JL, Casado M, Rodríguez M, Turnes J, Morano Amado LE, Morillas RM, Forns X, Pascasio Acevedo JM, Andrade RJ, Rivero A, Carrión JA, Lens S, Riveiro-Barciela M, McNabb B, Zhang G, Camus G, Stamm LM, Brainard DM, Subramanian GM, Buti M.

Gastroenterology. 2018 Oct;155(4):1120-1127.e4. doi: 10.1053/j.gastro.2018.06.042. Epub 2018 Jun 27.

PMID:
29958855
37.

The perception of colour and material in naturalistic tasks.

Brainard DH, Cottaris NP, Radonjić A.

Interface Focus. 2018 Aug 6;8(4):20180012. doi: 10.1098/rsfs.2018.0012. Epub 2018 Jun 15. Review.

38.

Letter: direct-acting anti-viral (DAA) therapy needs strong safety and efficacy check-authors' reply.

Singer AW, Reddy KR, Telep LE, Osinusi AO, Brainard DM, Buti M, Chokkalingam AP.

Aliment Pharmacol Ther. 2018 Jul;48(2):235-236. doi: 10.1111/apt.14820. No abstract available.

PMID:
29939414
39.

Illumination discrimination in the absence of a fixed surface-reflectance layout.

Radonjic A, Ding X, Krieger A, Aston S, Hurlbert AC, Brainard DH.

J Vis. 2018 May 1;18(5):11. doi: 10.1167/18.5.11.

40.

Significance of NS5B Substitutions in Genotype 1b Hepatitis C Virus Evaluated by Bioinformatics Analysis.

Uchida Y, Nakamura S, Kouyama JI, Naiki K, Motoya D, Sugawara K, Inao M, Imai Y, Nakayama N, Tomiya T, Hedskog C, Brainard D, Mo H, Mochida S.

Sci Rep. 2018 Jun 11;8(1):8818. doi: 10.1038/s41598-018-27291-7.

41.

Sofosbuvir/velpatasvir for 12 weeks in genotype 1-4 HCV-infected liver transplant recipients.

Agarwal K, Castells L, Müllhaupt B, Rosenberg WMC, McNabb B, Arterburn S, Camus G, McNally J, Stamm LM, Brainard DM, Mani Subramanian G, Mariño Z, Dufour JF, Forns X.

J Hepatol. 2018 Sep;69(3):603-607. doi: 10.1016/j.jhep.2018.05.039. Epub 2018 Jun 8.

PMID:
29886154
42.

Deferred treatment with sofosbuvir-velpatasvir-voxilaprevir for patients with chronic hepatitis C virus who were previously treated with an NS5A inhibitor: an open-label substudy of POLARIS-1.

Bourlière M, Gordon SC, Schiff ER, Tran TT, Ravendhran N, Landis CS, Hyland RH, Stamm LM, Zhang J, Dvory-Sobol H, Subramanian GM, Brainard DM, McHutchison JG, Serfaty L, Thompson AJ, Sepe TE, Curry MP, Reddy KR, Manns MP.

Lancet Gastroenterol Hepatol. 2018 Aug;3(8):559-565. doi: 10.1016/S2468-1253(18)30118-3. Epub 2018 May 31.

PMID:
29859740
43.

Effects of sofosbuvir-based hepatitis C treatment on the pharmacokinetics of tenofovir in HIV/HCV-coinfected individuals receiving tenofovir disoproxil fumarate.

MacBrayne CE, Marks KM, Fierer DS, Naggie S, Chung RT, Hughes MD, Kim AY, Peters MG, Brainard DM, Seifert SM, Castillo-Mancilla JR, Bushman LR, Anderson PL, Kiser JJ.

J Antimicrob Chemother. 2018 Aug 1;73(8):2112-2119. doi: 10.1093/jac/dky146.

44.

Erratum: Non-invasive assessment of human cone photoreceptor function: erratum.

Cooper RF, Tuten WS, Dubra A, Brainard DH, Morgan JIW.

Biomed Opt Express. 2018 Mar 22;9(4):1842. doi: 10.1364/BOE.9.001842. eCollection 2018 Apr 1.

45.

Ledipasvir/sofosbuvir with or without ribavirin for 8 or 12 weeks for the treatment of HCV genotype 4 infection: results from a randomised phase III study in Egypt.

Shiha G, Esmat G, Hassany M, Soliman R, Elbasiony M, Fouad R, Elsharkawy A, Hammad R, Abdel-Razek W, Zakareya T, Kersey K, Massetto B, Osinusi A, Lu S, Brainard DM, McHutchison JG, Waked I, Doss W.

Gut. 2019 Apr;68(4):721-728. doi: 10.1136/gutjnl-2017-315906. Epub 2018 Apr 17.

46.

Drug-Drug Interaction Profile of the Fixed-Dose Combination Tablet Regimen Ledipasvir/Sofosbuvir.

German P, Mathias A, Brainard DM, Kearney BP.

Clin Pharmacokinet. 2018 Nov;57(11):1369-1383. doi: 10.1007/s40262-018-0654-5. Review.

PMID:
29644537
47.

Ledipasvir/sofosbuvir for treatment-naive and treatment-experienced Chinese patients with genotype 1 HCV: an open-label, phase 3b study.

Wei L, Xie Q, Hou JL, Tang H, Ning Q, Cheng J, Nan Y, Zhang L, Li J, Jiang J, McNabb B, Zhang F, Camus G, Mo H, Osinusi A, Brainard DM, Gong G, Mou Z, Wu S, Wang G, Hu P, Gao Y, Jia J, Duan Z.

Hepatol Int. 2018 Mar;12(2):126-132. doi: 10.1007/s12072-018-9856-z. Epub 2018 Apr 10.

48.

Baseline Factors Associated With Improvements in Decompensated Cirrhosis After Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection.

El-Sherif O, Jiang ZG, Tapper EB, Huang KC, Zhong A, Osinusi A, Charlton M, Manns M, Afdhal NH, Mukamal K, McHutchison J, Brainard DM, Terrault N, Curry MP.

Gastroenterology. 2018 Jun;154(8):2111-2121.e8. doi: 10.1053/j.gastro.2018.03.022. Epub 2018 Mar 11.

PMID:
29535028
49.

Drug-Drug Interaction Studies Between Hepatitis C Virus Antivirals Sofosbuvir/Velpatasvir and Boosted and Unboosted Human Immunodeficiency Virus Antiretroviral Regimens in Healthy Volunteers.

Mogalian E, Stamm LM, Osinusi A, Brainard DM, Shen G, Ling KHJ, Mathias A.

Clin Infect Dis. 2018 Aug 31;67(6):934-940. doi: 10.1093/cid/ciy201.

PMID:
29522076
50.

Pharmacokinetics and Safety of Velpatasvir and Sofosbuvir/Velpatasvir in Subjects with Hepatic Impairment.

Mogalian E, Brainard DM, Osinusi A, Moorehead L, Murray B, Ling KHJ, Perry R, Curtis C, Lawitz E, Lasseter K, Marbury T, Mathias A.

Clin Pharmacokinet. 2018 Nov;57(11):1449-1457. doi: 10.1007/s40262-018-0645-6.

PMID:
29520729

Supplemental Content

Loading ...
Support Center